Phase 3 Readout~month
Phase 3 Topline: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575)
- Drug
- lisaftoclax
- Indication
- CLL/SLL
Other upcoming events for AAPG
Phase 3 ReadoutPhase 3 Topline: A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of AP
Phase 3 ReadoutPhase 3 Topline: A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investiga
Phase 3 ReadoutPhase 3 Topline: A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-257
Patent ExpiryPatent/Exclusivity Expiry: BOSULIF
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.